<DOC>
	<DOCNO>NCT02229955</DOCNO>
	<brief_summary>The purpose clinical Study Tisporin Eye Drops 0.05 % ( Cyclosporine ophthalmic solution ) group Restasis Eye Drops 0.05 % ( Cyclosporine ophthalmic suspension ) group 12 week treatment , treatment group comparison evaluation efficacy safety Moderate Severe Dry Eye Disease . - Corneal stain test , Ocular surface disease index ( OSDI ) , Tear break time ( TBUT ) , Non-anesthetic Schirmer test</brief_summary>
	<brief_title>Study Tisporin Eye Drops Group Restasis Eye Drops Group After Treatment , Each Treatment Group Comparisons Evaluation Efficacy Safety Moderate Severe Dry Eye Disease</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>[ Patients moderatetosevere ocular dry eye ] 1 . The One eye corneal fluorescein stain score 2 high ( Oxford grade ) 2 . Nonanesthetic Schirmer test value ≤ 10mm/5min patient least one eye score ( Nonanesthetic Schirmer test value = 0/5min , nasal stimulation eye , Schirmer test value ≥ 3mm/5min ) 3 . Tear breakup time 10 second less 4 . Screening eye , correct visual acuity 0.2 5 . Despite conventional treatment , symptom dry eye sign ( Artificial tear eye drop , sympathetic nervous system stimulant agent , parasympathetic nerve stimulant , etc . ) 1 . Screening visit previous 3 month ( 12 week ) participate clinical trial cyclosporine eye drop , use cyclosporin ophthalmic solution . 2 . The patient systemic ocular disorder affect test result ( ocular surgery , trauma , disease ) 1 . Abnormal eyelid function : Disoders eyelids eyelash 2 . Ocular allergy currently treatment allergic disease eye ( topical ocular mast cell stabilizer , antihistamine use , etc . ) 3 . Cicatricial keratoconjunctivitis cause herpetic keratopathy , conjunctival scarring ( alkali damage , StevenJohnson syndrome , cicatricial pemphigoid ) , pterygium , pinguecula , lack congenital lacrimal , neurogenic keratitis , keratoconus , corneal transplantation 3. current recent patient use dry eye syndrome medication ( topical systemic ) may affect status 4 . The use clinical trial drug hypersensitivity reaction patient</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Dry Eye Syndromes</keyword>
</DOC>